CA2306444A1 - Inhibition de la replication du virus de l'immunodeficience humaine (vih-1) - Google Patents

Inhibition de la replication du virus de l'immunodeficience humaine (vih-1) Download PDF

Info

Publication number
CA2306444A1
CA2306444A1 CA002306444A CA2306444A CA2306444A1 CA 2306444 A1 CA2306444 A1 CA 2306444A1 CA 002306444 A CA002306444 A CA 002306444A CA 2306444 A CA2306444 A CA 2306444A CA 2306444 A1 CA2306444 A1 CA 2306444A1
Authority
CA
Canada
Prior art keywords
cell
hiv
vector
cells
pkr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002306444A
Other languages
English (en)
Inventor
Robert J. Suhadolnik
Martin E. Adelson
Kathryn T. Iacono
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temple University of Commonwealth System of Higher Education
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2306444A1 publication Critical patent/CA2306444A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • AIDS & HIV (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Cette invention se rapporte à un système antiviral avec régulation du VIH-1. Cette invention propose des produits de synthèse et des procédés permettant de transférer une enzyme antivirale dans des cellules cibles, où cette enzyme se trouve soumise à une régulation du VIH-1. L'infection par VIH-1 de ces cellules cibles entraîne l'activation de l'enzyme antivirale et aboutit à l'inhibition de la réplication virale. Cette approche antivirale contre le VIH-1 peut être combinée avec des approches chimiothérapeutiques traditionnelles, ce qui permet de réduire considérablement l'utilisation des médicaments antiviraux, avec une baisse des effets secondaires qui les accompagnent, et de maintenir le VIH-1 dans un état latent réel.
CA002306444A 1997-10-16 1998-10-15 Inhibition de la replication du virus de l'immunodeficience humaine (vih-1) Abandoned CA2306444A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6198497P 1997-10-16 1997-10-16
US60/061,984 1997-10-16
PCT/US1998/021880 WO1999019496A1 (fr) 1997-10-16 1998-10-15 Inhibition de la replication du virus de l'immunodeficience humaine (vih-1)

Publications (1)

Publication Number Publication Date
CA2306444A1 true CA2306444A1 (fr) 1999-04-22

Family

ID=22039490

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002306444A Abandoned CA2306444A1 (fr) 1997-10-16 1998-10-15 Inhibition de la replication du virus de l'immunodeficience humaine (vih-1)

Country Status (5)

Country Link
EP (1) EP1029062A1 (fr)
JP (1) JP2001520017A (fr)
AU (1) AU1189899A (fr)
CA (1) CA2306444A1 (fr)
WO (1) WO1999019496A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2484251C (fr) 2002-04-30 2015-06-23 University Of South Florida Matieres et procedes visant a prevenir et a traiter des maladies provoquees par des virus a arn
US7595303B1 (en) 2002-09-05 2009-09-29 University Of South Florida Genetic adjuvants for immunotherapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5738985A (en) * 1993-04-02 1998-04-14 Ribogene, Inc. Method for selective inactivation of viral replication

Also Published As

Publication number Publication date
AU1189899A (en) 1999-05-03
EP1029062A1 (fr) 2000-08-23
JP2001520017A (ja) 2001-10-30
WO1999019496A1 (fr) 1999-04-22

Similar Documents

Publication Publication Date Title
US5861290A (en) Methods and polynucleotide constructs for treating host cells for infection or hyperproliferative disorders
EP0454781B1 (fr) Cellules de recombinaison pour des therapies d'infections et de troubles hyperproliferatifs et la preparation de ces cellules
MX2007010008A (es) Vectores lentivirales y su uso.
JPH10507905A (ja) ヒト血清による溶解耐性生産者細胞系で生産されるレトロウイルスベクター
US20140170709A1 (en) Vector for gene therapy
ROGERS et al. Killing Epstein-Barr virus-positive B lymphocytes by gene therapy: comparing the efficacy of cytosine deaminase and herpes simplex virus thymidine kinase
Adelson et al. Inhibition of human immunodeficiency virus (HIV‐1) replication in SupT1 cells transduced with an HIV‐1 LTR‐driven PKR cDNA construct
Qiao et al. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment
AU749059B2 (en) Therapeutic use of lentiviral vectors
US6677155B1 (en) Triple hybrid amplicon vector systems to generate retroviral packaging lines
CA2306444A1 (fr) Inhibition de la replication du virus de l'immunodeficience humaine (vih-1)
NZ326429A (en) A producer cell containing a DNA sequence lacks functional env and functional gag-pol genes capable of producing a retroviral vector containing neither and its use in gene therapy
Marcello et al. Inducible expression of herpes simplex virus thymidine kinase from a bicistronic HIV1 vector
US6130089A (en) Materials and methods for gene transfer
Budzik Generation and Characterization of a Foamy Virus-Based Replicating Retroviral Vector System for Cancer Therapy
Joseph Non-integrating integrase and long terminal repeat attachment site mutant HIV-1-derived lentiviral vectors
US6063374A (en) Recombinant HIV and modified packaging cells and method for using
CA2047363C (fr) Therapies a base de recombinaison pour les infections et troubles hyperproliferatifs
AU2004202502B2 (en) Retroviral particles protected against complement mediated destruction
Rabson Fratricidal retroviruses: a new twist in gene therapy
WO2000065077A1 (fr) Systeme de vecteurs d'amplicons hybrides triples pour la generation de lignees d'encapsidation
Morrey The characterization of drug resistance genes for in vivo hematopoietic stem cell selection
Medin Molecular Therapeutics in Hematology: Gene Therapy
Tzeng et al. Oxide Synthase Expression

Legal Events

Date Code Title Description
FZDE Dead